NEWS BRIEF · Research journal
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
From the report
Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04710-1In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.

